Walleye Capital
ARCT icon

Walleye Capital’s Arcturus Therapeutics ARCT Stock Holding History

Walleye Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,200
Closed -$68.7K – 4354
2025
Q4 		$68.7K Sell
11,200
-6,200
-36% -$67K ﹤0.01% 3998
2025
Q3 		$321K Buy
17,400
+1,200
+7% +$19.3K ﹤0.01% 2960
2025
Q2 		$211K Buy
+16,200
New +$192K ﹤0.01% 3322
2025
Q1 		– Sell
-100
Closed -$1.7K – 4224
2024
Q4 		$1.7K Buy
+100
New +$1.88K ﹤0.01% 4670
2024
Q3 		– Sell
-10,600
Closed -$258K – 5243
2024
Q2 		$258K Buy
10,600
+3,300
+45% +$100K ﹤0.01% 4104
2024
Q1 		$247K Buy
+7,300
New +$259K ﹤0.01% 3827

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's ARCT Position: Q1 2026 in Review

Walleye Capital sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 1 share — an estimated $6 sold.

Walleye Capital first reported a position in ARCT in Q1 2021 and held it in 5 quarters. The position peaked at $1.07M in Q2 2022. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Walleye Capital reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 1 Arcturus Therapeutics share in Q1 2026, an estimated $6.
  • Walleye Capital first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 5 quarters.
  • Walleye Capital's Arcturus Therapeutics position peaked at $1.07M in Q2 2022.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.